Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs - 2The Most Notable Design Brands of the 21st Hundred years
- 3The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- 4Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- 5Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- 6 Famous kind of practice on the planet
- Little Urban areas to Visit in Western Europe
- Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- Germany and trade unions kick off tough public-sector wage talks
- From Representative to Business visionary: Private issue Victories
- The Best Cell phone Brands for Tech Lovers
- What loving-kindness meditation is and how to practice it in the new year
- Figure out How to Adjust Your Handshake to Various Societies
- 6 Web-based Course Stages for Successful Learning and Educating
